<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532971</url>
  </required_header>
  <id_info>
    <org_study_id>17-664</org_study_id>
    <nct_id>NCT03532971</nct_id>
  </id_info>
  <brief_title>Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes</brief_title>
  <official_title>Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating the reactivation of BK virus in patients who have undergone&#xD;
      allogeneic hematopoietic-cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Every year, more than 25,000 patients worldwide receive lifesaving bone marrow&#xD;
      transplantations with hematopoietic-cells from another person. It is estimated that over 75%&#xD;
      of these patients will develop an infectious complication, of which approximately one third&#xD;
      can be life-threatening. A significant proportion of these infections are caused by&#xD;
      opportunistic viruses, such as BK virus.&#xD;
&#xD;
      This virus establishes latent infection in most individuals, but does not normally cause&#xD;
      disease. It can reactivate after hematopoietic-cell transplantation and represents the second&#xD;
      most common viral infection in this patient population. BK virus is associated with kidney&#xD;
      failure and a decreased chance of survival after hematopoietic-cell transplantation. There&#xD;
      are no effective antiviral treatments for this disease.&#xD;
&#xD;
      Despite being the second most common cause of clinical disease hematopoietic-cell&#xD;
      transplantation, very little is known about this virus. To address this knowledge gap, the&#xD;
      investigators aim to study patients with confirmed BK virus disease post allogeneic&#xD;
      hematopoietic-cell transplantation.&#xD;
&#xD;
      As part of this study, regular urine and blood tests will be done to understand how the virus&#xD;
      behaves over time and which organs it affects. Blood and urine samples will also be obtained&#xD;
      to study how the immune system rebuilds itself after hematopoietic-cell transplantation.&#xD;
      Finally, an ultrasound of the kidneys and the bladder will be done to evaluate for any&#xD;
      presence of disease in these organs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The mean total number of cytokine producing BKV-specific NK and T-cells at the time of BKVD in affected patients, as compared with unaffected patients</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analytically determine a BKV-specific cfDNA methylation pattern in the urine and plasma samples of affected patients</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analytically determine BKV-specific antibody glycosylation patterns in plasma samples of patients who exhibit BKVR.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>BK Virus Infection</condition>
  <arm_group>
    <arm_group_label>allogeneic hematopoietic-cell transplantation patients</arm_group_label>
    <description>Prospective HCT cohort of patients undergoing allogeneic HCT at DFCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Symptom index questionnaire</intervention_name>
    <description>A survey administered to identify the symptoms of the patient</description>
    <arm_group_label>allogeneic hematopoietic-cell transplantation patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>BK polyomavirus PCR</intervention_name>
    <description>quantitative PCR testing</description>
    <arm_group_label>allogeneic hematopoietic-cell transplantation patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality of life questionnaires</intervention_name>
    <description>Standard questionnaires validated for HCT recipients</description>
    <arm_group_label>allogeneic hematopoietic-cell transplantation patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients who undergo allo-HCT will be eligible for the study, regardless of age,&#xD;
        underlying disease, conditioning regimen, or GVHD prophylaxis regimen&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult â‰¥18 years old&#xD;
&#xD;
          -  All adult patients who undergo allo-HCT will be eligible for the study, regardless of&#xD;
             age, underlying disease, conditioning regimen, or GVHD prophylaxis regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jerome Ritz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 10, 2018</study_first_submitted>
  <study_first_submitted_qc>May 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jerome Ritz, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>BK virus</keyword>
  <keyword>BK polyomavirus</keyword>
  <keyword>hematopoietic-cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

